Uwe , A. Wittel, and Apollina, Goel and Varshney, Grish C and Batra, Surinder K. (2001) Mucin antibodies- New tools in diagnosis and therapy of cancer. Frontiers in Bioscience, 6. pp. 1296-1310.
![[img]](http://crdd.osdd.net/open/style/images/fileicons/application_pdf.png) |
PDF
varshney2001.pdf - Published Version Restricted to Registered users only Download (979Kb) | Request a copy |
Abstract
Many cancer and diseased cells are distinguished from their normal counterparts by an altered expression of cell-surface epitopes. One family of molecules that show altered expression on tumor cells is mucins (MUC). Unlike normal tissue where MUC exists as heavily glycosylated form, the disease- or tumor-associated MUC molecules are underglycosylated. Such underglycosylation of the core protein in cancer tissues exposes new epitopes on the cell surface that are unique to cancer tissues. Several monoclonal antibodies (Mabs) have been generated against these normal and tumor-associated mucins. Enzymatic fragments of Mabs like F(ab’)2 and Fab have shown improved clinical utility for diagnosis, imaging, and therapy of cancer. Genetic-engineering methods have been used to design antibody fragments exhibiting high functional affinity, good tumor localization, and rapid clearance from the blood stream thus minimizing radiation exposure to the normal tissues. Such recombinant fragments have shown encouraging results in preclinical studies using xenografted tumor bearing mice and present a whole new avenue for radioimmunotherapy and diagnosis of cancer.
| Item Type: | Article |
|---|---|
| Additional Information: | Copyright of this article belongs to Bioscience.org. |
| Subjects: | Q Science > QR Microbiology |
| Depositing User: | Dr. K.P.S.Sengar |
| Date Deposited: | 03 Feb 2012 05:50 |
| Last Modified: | 07 Jan 2015 05:31 |
| URI: | http://crdd.osdd.net/open/id/eprint/862 |
Actions (login required)
 |
View Item |
